{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:28:35Z","timestamp":1792384115563,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021RIS-001"],"award-info":[{"award-number":["2021RIS-001"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009819","name":"Busan Metropolitan City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2022R1C1C1006059"],"award-info":[{"award-number":["NRF-2022R1C1C1006059"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1063144"],"award-info":[{"award-number":["NRF-2022R1F1A1063144"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clinre.2023.102227","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T05:55:48Z","timestamp":1698126948000},"page":"102227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Hyejung","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-8564","authenticated-orcid":false,"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-9376","authenticated-orcid":false,"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-699X","authenticated-orcid":false,"given":"Jae-Hwan","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-0565","authenticated-orcid":false,"given":"In-hwan","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2023.102227_bib0001","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2023.102227_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-021-01974-4","article-title":"The liver steatosis severity and lipid characteristics in primary biliary cholangitis","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clinre.2023.102227_bib0004","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102227_bib0005","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2023.102227_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2023.09.006","article-title":"The new international nomenclature for steatotic liver disease: one step forward towards enhanced awareness for healthier life","author":"van Erpecum","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clinre.2023.102227_bib0007","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.clinre.2023.102227_bib0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0009","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102227_bib0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.cgh.2021.03.005","article-title":"Treatment candidacy for pharmacologic therapies for NASH","volume":"20","author":"Rowe","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115776","article-title":"Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders","volume":"216","author":"Fiorucci","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinre.2023.102227_bib0012","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0013","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2016.1216784","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"10","author":"Jones","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0014","doi-asserted-by":"crossref","first-page":"e00368","DOI":"10.1002\/prp2.368","article-title":"Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinre.2023.102227_bib0015","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102227_bib0016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid\u2014a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br Med Bull"},{"key":"10.1016\/j.clinre.2023.102227_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2023.102227_bib0018","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"32","author":"Chatrath","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.clinre.2023.102227_bib0019","doi-asserted-by":"crossref","first-page":"e0005","DOI":"10.1097\/HC9.0000000000000005","article-title":"Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals","volume":"7","author":"Ng","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2023.102227_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.clinre.2023.102227_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinre.2023.102227_bib0022","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102227_bib0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2023.102227_bib0024","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2023.102227_bib0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2023.102227_bib0026","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2023.102227_bib0027","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clinre.2023.102227_bib0028","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted Disruption of the Nuclear Receptor FXR\/BAR Impairs Bile Acid and Lipid Homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.clinre.2023.102227_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173616","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: insights into liver disorders and liver cancer","volume":"889","author":"Guan","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinre.2023.102227_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8829510","article-title":"Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: a Meta-Analysis","volume":"2021","author":"Gao","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0032","first-page":"1","article-title":"Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis","volume":"1","author":"Aishwarya","year":"2022","journal-title":"RPS Pharm Pharmacol Rep"},{"key":"10.1016\/j.clinre.2023.102227_bib0033","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2023.102227_bib0034","article-title":"Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: current Status","volume":"12","author":"Roy","year":"2022","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"10.1016\/j.clinre.2023.102227_bib0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/MEG.0000000000001785","article-title":"Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review","volume":"32","author":"Li","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101675","article-title":"Efficacy and safety of obeticholic acid in liver disease\u2014a systematic review and meta-analysis","volume":"45","author":"Kulkarni","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2023.102227_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2020.0028","article-title":"Current understanding of primary biliary cholangitis","volume":"27","author":"Tanaka","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2023.102227_bib0038","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3350\/cmh.2017.0066","article-title":"Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea","volume":"24","author":"Jeong","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0041","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/jgh3.12349","article-title":"Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a focused literature review","volume":"4","author":"Eguchi","year":"2020","journal-title":"JGH Open"},{"key":"10.1016\/j.clinre.2023.102227_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100727","article-title":"The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010 and 2020: a population-based study","volume":"27","author":"Hamid","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinre.2023.102227_bib0043","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/beem.2002.0225","article-title":"Obesity and liver disease","volume":"16","author":"Scheen","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:20Z","timestamp":1761896120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740123001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2210740123001523"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102227","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102227"}}